Keyur P. Patel

25.5k total citations
334 papers, 8.6k citations indexed

About

Keyur P. Patel is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Keyur P. Patel has authored 334 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Hematology, 141 papers in Genetics and 85 papers in Molecular Biology. Recurrent topics in Keyur P. Patel's work include Acute Myeloid Leukemia Research (151 papers), Chronic Lymphocytic Leukemia Research (70 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (70 papers). Keyur P. Patel is often cited by papers focused on Acute Myeloid Leukemia Research (151 papers), Chronic Lymphocytic Leukemia Research (70 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (70 papers). Keyur P. Patel collaborates with scholars based in United States, Japan and Canada. Keyur P. Patel's co-authors include L. Jeffrey Medeiros, Hagop M. Kantarjian, Rajyalakshmi Luthra, Mark J. Routbort, Farhad Ravandi, Jörge E. Cortes, Guillermo Garcia‐Manero, Bedia A. Barkoh, Rashmi Kanagal‐Shamanna and Elias Jabbour and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Keyur P. Patel

316 papers receiving 8.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keyur P. Patel United States	48	4.0k	2.8k	2.4k	2.0k	2.0k	334	8.6k
Meir Wetzler United States	48	5.0k 1.2×	3.0k 1.1×	2.1k 0.9×	2.1k 1.1×	885 0.5×	245	8.6k
Christian Récher France	49	5.0k 1.2×	4.4k 1.6×	1.8k 0.7×	1.9k 1.0×	712 0.4×	299	9.1k
Rajyalakshmi Luthra United States	65	4.1k 1.0×	5.0k 1.7×	3.6k 1.5×	3.6k 1.8×	3.8k 1.9×	308	13.7k
Pellegrino Musto Italy	52	5.6k 1.4×	4.3k 1.5×	2.4k 1.0×	3.5k 1.8×	731 0.4×	386	9.7k
Claude Preudhomme France	62	9.4k 2.3×	5.7k 2.0×	4.4k 1.8×	2.4k 1.2×	1.4k 0.7×	356	13.3k
Eva Hellström‐Lindberg Sweden	40	8.2k 2.0×	4.0k 1.4×	3.8k 1.6×	1.2k 0.6×	721 0.4×	187	10.6k
Uwe Platzbecker Germany	54	8.8k 2.2×	3.6k 1.3×	4.1k 1.7×	1.7k 0.9×	692 0.4×	543	11.3k
Rami S. Komrokji United States	45	5.5k 1.3×	2.6k 0.9×	3.1k 1.3×	1.2k 0.6×	403 0.2×	584	7.5k
Courtney D. DiNardo United States	53	10.1k 2.5×	6.6k 2.3×	3.3k 1.4×	2.6k 1.3×	1.5k 0.8×	628	13.5k
Robert B. Gerbing United States	51	3.9k 1.0×	4.6k 1.6×	1.3k 0.5×	2.1k 1.1×	2.1k 1.1×	239	11.0k

Countries citing papers authored by Keyur P. Patel

Since Specialization

Citations

This map shows the geographic impact of Keyur P. Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyur P. Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyur P. Patel more than expected).

Fields of papers citing papers by Keyur P. Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyur P. Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyur P. Patel. The network helps show where Keyur P. Patel may publish in the future.

Co-authorship network of co-authors of Keyur P. Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Keyur P. Patel. A scholar is included among the top collaborators of Keyur P. Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyur P. Patel. Keyur P. Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Richard K., Fatima Zahra Jelloul, Rajyalakshmi Luthra, et al.. (2025). Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time. JCO Precision Oncology. 9(9). e2400299–e2400299. 2 indexed citations

Gouda, Mohamed A., Filip Jankú, Ying Yuan, et al.. (2025). Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research. 31(20). 4299–4310. 1 indexed citations

Senapati, Jayastu, H. Kantarjian, Edward Ayoub, et al.. (2024). Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up. Blood. 144(Supplement 1). 1513–1513. 1 indexed citations

Lucas, F. Anthony San, Keyur P. Patel, Wai Chin Foo, et al.. (2024). Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3612–3612.

Simonian, Narina, et al.. (2023). Predictors of early and long-term readmissions and their association with survival after liver transplantation. 13. 100195–100195.

Daniels, Molly S., Ecaterina E. Dumbrava, Ying Yuan, et al.. (2023). Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. SHILAP Revista de lepidopterología. 7(1). 7–17. 1 indexed citations

Patel, Keyur P., et al.. (2023). A Five-Year Clinical Course of Potential Phenocopy Syndrome of Behavioral Variant Frontotemporal Dementia: A Case Report and Literature Review. Cureus. 15(6). e40118–e40118. 1 indexed citations

Senapati, Jayastu, Sanam Loghavi, Nicholas J. Short, et al.. (2023). Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 142(19). 1647–1657. 35 indexed citations

Jabbour, Elias, Koji Sasaki, Fadi Haddad, et al.. (2023). The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors. American Journal of Hematology. 98(4). 658–665. 15 indexed citations

10.

Senapati, Jayastu, Mahran Shoukier, Guillermo Garcia‐Manero, et al.. (2022). Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology. 97(5). 574–582. 15 indexed citations

11.

Borthakur, Gautam, Farhad Ravandi, Keyur P. Patel, et al.. (2022). Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. American Journal of Hematology. 97(11). 1427–1434. 20 indexed citations

12.

Sasaki, Koji, Farhad Ravandi, Tapan M. Kadia, et al.. (2022). Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology. 97(7). 865–876. 13 indexed citations

13.

Chifotides, Helen T., Lucia Masárová, Mansour Alfayez, et al.. (2020). Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Advances. 4(21). 5336–5342. 37 indexed citations

14.

Lachowiez, Curtis A., Sarah A. Bannon, Sanam Loghavi, et al.. (2020). Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology. 95(11). E313–E315. 3 indexed citations

15.

Quesada, Andres, Mark J. Routbort, Courtney D. DiNardo, et al.. (2019). DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease. American Journal of Hematology. 94(7). 757–766. 71 indexed citations

16.

Sasaki, Koji, Hagop M. Kantarjian, Tapan M. Kadia, et al.. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia. Cancer. 125(21). 3755–3766. 36 indexed citations

17.

Chen, Hui, Rajyalakshmi Luthra, Mark J. Routbort, et al.. (2018). Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Molecular Cancer Therapeutics. 17(7). 1575–1584. 70 indexed citations

18.

Ishizawa, Jo, Kenji Nakamaru, Takahiko Seki, et al.. (2018). Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Research. 78(10). 2721–2731. 44 indexed citations

19.

Estrella, Jeannelyn S., Michael T. Tetzlaff, Roland L. Bassett, et al.. (2015). Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Molecular Cancer Therapeutics. 14(12). 2887–2895. 33 indexed citations

20.

Goswami, Rashmi S., Keyur P. Patel, Rajesh R. Singh, et al.. (2015). Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research. 21(11). 2644–2651. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact